These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20007955)

  • 41. Low trough serum infliximab and antibodies to infliximab in smokers.
    Kong JY; Bundell C; Pawlik J; Hollingsworth P; Forbes G
    Inflamm Bowel Dis; 2013 Mar; 19(3):E35-6. PubMed ID: 22345044
    [No Abstract]   [Full Text] [Related]  

  • 42. The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease.
    Sheasgreen C; Nguyen GC
    Curr Gastroenterol Rep; 2017 May; 19(5):19. PubMed ID: 28397129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
    Feagan BG; Reinisch W; Rutgeerts P; Sandborn WJ; Yan S; Eisenberg D; Bala M; Johanns J; Olson A; Hanauer SB
    Am J Gastroenterol; 2007 Apr; 102(4):794-802. PubMed ID: 17324131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Infliximab for ulcerative colitis.
    Simmons J; Jewell DP
    Dig Liver Dis; 2002 Sep; 34(9):616-8. PubMed ID: 12405245
    [No Abstract]   [Full Text] [Related]  

  • 45. Pustular psoriasis induced by infliximab.
    Thurber M; Feasel A; Stroehlein J; Hymes SR
    J Drugs Dermatol; 2004; 3(4):439-40. PubMed ID: 15303790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Infliximab in the treatment of severe ulcerative colitis: a follow-up study.
    Kohn A; Prantera C; Pera A; Cosintino R; Sostegni R; Daperno M
    Eur Rev Med Pharmacol Sci; 2004; 8(5):235-7. PubMed ID: 15638237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Infliximab as treatment for a severe outbreak of ulcerative colitis].
    Ruiz P; San Salvador P; Ortiz de Zárate J; Cabezudo P; Marcé L; Polo F; Blanco S; Orive V
    Gastroenterol Hepatol; 2004; 27(7):430-1. PubMed ID: 15461945
    [No Abstract]   [Full Text] [Related]  

  • 48. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease.
    Vespasiani Gentilucci U; Caviglia R; Picardi A; Carotti S; Ribolsi M; Galati G; Petitti T; Afeltra A; Cicala M
    Aliment Pharmacol Ther; 2005 May; 21(9):1063-71. PubMed ID: 15854167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infliximab in the treatment of severe ulcerative colitis.
    Jiménez JM
    Rev Esp Enferm Dig; 2004 Feb; 96(2):89-93. PubMed ID: 15255017
    [No Abstract]   [Full Text] [Related]  

  • 50. Infliximab for ulcerative colitis.
    Actis GC
    Am J Gastroenterol; 2003 Mar; 98(3):709. PubMed ID: 12650824
    [No Abstract]   [Full Text] [Related]  

  • 51. Anti-tumor necrosis factor therapy for ulcerative colitis.
    Kountouras J; Zavos C; Chatzopoulos D
    Gastroenterology; 2005 Sep; 129(3):1138-9. PubMed ID: 16143158
    [No Abstract]   [Full Text] [Related]  

  • 52. [Ulcerative colitis associated with rectocolitis hemorrhagic: successful treatment with infliximab].
    Godart B; Beau P; Benchellal Z; Bumsel F; Metman E
    Gastroenterol Clin Biol; 2007 Jan; 31(1):88-90. PubMed ID: 17273137
    [No Abstract]   [Full Text] [Related]  

  • 53. [Treatment with infliximab of peristomal pyoderma gangrenosum in ulcerative colitis].
    Krag AA; Gjersøe P
    Ugeskr Laeger; 2005 May; 167(18):1968-9. PubMed ID: 15929274
    [No Abstract]   [Full Text] [Related]  

  • 54. Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients.
    Santacana Juncosa E; Padullés Zamora A; Colom Codina H; Rodríguez Alonso L; Guardiola Capo J; Bas Minguet J; Padullés Zamora N
    Rev Esp Enferm Dig; 2016 Feb; 108(2):104-5. PubMed ID: 26838495
    [No Abstract]   [Full Text] [Related]  

  • 55. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis.
    Yang Z; Wu Q; Wu K; Fan D
    Aliment Pharmacol Ther; 2010 Feb; 31(4):486-92. PubMed ID: 19925496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Contemporary views on non-specific ulcerative colitis and conservative methods of its treatment ].
    Bakulin IG; Stanke DA
    Voen Med Zh; 2008 Nov; 329(11):50-4. PubMed ID: 19186525
    [No Abstract]   [Full Text] [Related]  

  • 58. Infliximab for ulcerative colitis.
    Chey WY; Shah A
    J Clin Gastroenterol; 2005; 39(10):920; author reply 920. PubMed ID: 16208122
    [No Abstract]   [Full Text] [Related]  

  • 59. Management of acute severe ulcerative colitis.
    Doherty GA; Cheifetz AS
    Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):395-405. PubMed ID: 19673626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Annular purpura and ulcerative colitis: response to infliximab.
    Tan V; Bartlett M; Hosking P; Gibson PR
    Dig Liver Dis; 2007 May; 39(5):488-9. PubMed ID: 17383245
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.